Cutaneous and mucocutaneous leishmaniasis: Emerging therapies and progress in disease management

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 4, 2010, Pages 557-569

  Ameen, Mahreen ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cutaneous leishmaniasis; Leishmania; New World; Old World; Therapy

Indexed keywords

AMPHOTERICIN; ANTILEISHMANIAL AGENT; ANTIMONY; AZITHROMYCIN; BISPHOSPHONIC ACID DERIVATIVE; BUPARVAQUONE; GENTAMICIN; IMIQUIMOD; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PENTOXIFYLLINE; PLACEBO; PYRAZINAMIDE; SITAMAQUINE; STIBOGLUCONATE SODIUM; TAMOXIFEN; UNCLASSIFIED DRUG; WR 279 396;

AMERICAN LEISHMANIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRYOTHERAPY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TOLERABILITY; GENETIC HETEROGENEITY; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHERMIC THERAPY; IMMUNOMODULATION; IMMUNOTHERAPY; LEISHMANIA; LOW DRUG DOSE; MIXED INFECTION; MUCUCUTANEOUS LEISHMANIASIS; NAUSEA AND VOMITING; NONHUMAN; PARASITIC SKIN DISEASE; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN LEISHMANIASIS; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

ANTIPROTOZOAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTHERMIA, INDUCED; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LEISHMANIA; LEISHMANIASIS, MUCOCUTANEOUS; PHOTOCHEMOTHERAPY; PHYSICAL THERAPY MODALITIES;

EID: 77249103184     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903555219     Document Type: Review

References (108)

1. Ameen M. Cutaneous leishmaniasis: therapeutic strategies and future directions. Expert Opin Pharmacother 2007;8(16):2689-99
2. World Health Organization (2009). Leishmaniasis: burden of disease. Available from: http://www.who.int/leishmaniasis/burden/en. [Accessed 11 October 2009]
3. Desjeux P. Leishmaniasis: current situation and new perpectives. Comp Immunol Microbiol Infect Dis 2004;27:305-18
4. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmanaisis. PLoS Negl Trop Dis 2008;2(10):e313
5. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001;95:239-43
6. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol 2006;22(12):552-7
7. Kassi M, Kassi M, Afghan AK, et al. Marring leishmaniasis: the stigmatization and the impact of cutaneous leishmaniasis in pakistan and afghanistan. PLoS Negl Trop Dis 2008;2(10):e259
8. Weina PJ, Neafie RC, Wortmann G, et al. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis 2004;39(11):1674-80
9. Zeegelaar JE, Steketee WH, van Thiel PP, et al. Changing pattern of imported cutaneous leishmaniasis in the Netherlands. Clin Exp Dermatol 2005;30(1):1-5
10. Lawn SD, Whetham J, Chiodini PL, et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM 2004;97(12):781-8
11. Dujardin JC, Campino L, Cañavate C, et al. Spread of vector-borne diseases and neglect of leishmaniasis, Europe. Emerg Infect Dis 2008;14(7):1013-8
12. Maroli M, Rossi L, Baldelli R, et al. The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Trop Med Int Health 2008;13(2):256-64
13. Wright NA, Davis LE, Aftergut KS, et al. Cutaneous leishmaniasis in Texas: a northern spread of endemic areas. J Am Acad Dermatol 2008;58:650-2
14. Drugs for Neglected Diseases initiative (DNDi). Available from: www.dndi.org. [Accessed 18 October 2009]
15. Mansueto P, Vitale G, Di Lorenzo G, et al. Immunopathology of leishmaniasis: an update. Int J Immunopathol Pharmacol 2007;20(3):435-45
16. Couppie P, Clyti E, Sobesky M, et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 2004;151(6):1165-71
17. Padovese V, Terranova M, Toma L, et al. Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns. Trans R Soc Trop Med Hyg 2009;103(7):707-11
18. Rojas R, Valderrama L, Valderrama M, et al. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 2006;193(10):1375-83
19. Hadighi R, Mohebali M, Boucher P, et al. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 2006;3(5):e162
20. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006;19(1):111-26
21. Roussel M, Nacher M, Fremont G, et al. Comparison between one and two injections of pentamidine isethionate, at 7mg/kg in each injection, in the treatment of cutaneous leishmanaisis in French Guiana. Am Trop Med Parasitol 2006;100(4):307-14
22. Lai A, Fat EJ, Vrede MA, et al. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in suriname. Int J Dermatol 2002;41:796-800
23. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993;16(3):417-25
24. van der Meide WF, Sabajo LO, Jensema AJ, et al. Evaluation of treatment with pentamidine for cutaneous leishmaniasis in suriname. Int J Dermatol 2009;48(1):52-8
25. Bourreau E, Ronet C, Darsissac E, et al. In leishmaniasis due to Leishmania guyanensis infection, distinct intralesional interleukin-10 and Foxp3 mRNA expression are associated with unresponsiveness to treatment. J Infect Dis 2009;199(4):576-9
26. Bryceson AD. Diffuse cutaneous leishmaniasis in Ethiopia. II. Treatment. Trans R Soc Trop Med Hyg 1970;64(3):369-79
27. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987;36(16):2633-6
28. Zufferey R, Mamoun CB. Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs. Mol Biochem Parasitol 2002;125(1-2):127-34
29. Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004;38:1266-72
30. Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008;78(2):210-1
31. Mohebali M, Fotouhi A, Hooshmand B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007;103(1):33-40
32. Zerpa O, Ulrich M, Blanco B, et al. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 2007;156(6):1328-35
33. Belay AD, Asafa Y, Mesure J, Davidson RN. Successful miltefosine treatment of post kala-azar dermal leishmaniasis occurring during antiretroviral therapy. Ann Trop
34. Med Parasitol 2006;100(3):223-7
35. Sundar S, Kumar K, Chakravarty J, et al. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Trans R Soc Trop Med Hyg 2006;100(7):698-700
36. Guffanti M, Gaiera G, Bossolasco S, et al. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine. Am J Trop Med Hyg 2008;79(5):715-8
37. Perez-Victoria FJ, Sanchez-Canete MP, Seifert K, et al. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat 2006;9(1-2):26-39
38. Dorlo TP, van Thiel PP, Huitema AD, et al. Pharmacokinetics of miltefosine in old world cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008;52(8):2855-60
39. Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008;47(8):1000-6
40. Neal RA, Allen S, McCoy N, et al. The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 1995;35:577-84
41. Sundar S, Jha YK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Eng J Med 2007;356:2571-81
42. Hepburn NC, Tidman MJ, Hunter JA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1994;88(6):700-3
43. Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1994;88(6):695-8
44. El-On J, Sulitzeanu A, Schnur LF. Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin- methylbenzethonium chloride ointment. Ann Trop Med Parasitol 1991;85(3):323-8
45. Fong D, Chan MM, Rodriguez R, et al. Paromomycin resistance in Leishmania tropica: lack of correlation with mutation in the small subunit ribosomal RNA gene. Am J Trop Med Hyg 1994;51(6):758-66
46. den Boer ML, Alvar J, Davidson RN, et al. Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs 2009;14(3):395-410
47. El-On J, Jacobs JP, Weinrauch L. Topical chemotherapy of cutaneous leishmaniasis. Parasitol Today 1988;4:76-81
48. Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 2009;3(2):e381
49. Grogl M, Schuster BG, Ellis WY, Berman JD. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J Parasitol 1999;85:354-9
50. Ben Salah A, Buffet PA, Morizot G, et al. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 2009;3(5):e432
51. Lecoeur H, Buffet P, Morizot G, et al. Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 model. PLoS Negl Trop Dis 2007;1(2):e34
52. Carneiro G, Santos DC, Oliveira MC, et al. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res 2009. [Epub ahead of print]
53. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (glucantime) vs. cryotherapy and intralesional meglumine antimoniate (glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004;43(4):281-3
54. Salmanpour R, Razmavar MR, Abtahi N. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006;45(9):1115-6
55. Berman JD, Neva FA. Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro. Am J Trop Med Hyg 1981;30(2):318-21
56. Sacks DL, Barral A, Neva FA. Thermosensitivity patterns of old vs. new world cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro. Am J Trop Med Hyg 1983;32(2):300-4
57. Reithinger R, Mohsen M, Wahid M, et al. The efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized controlled trial. Clin Infect Dis 2005;40:1148-55
58. Vega JC, Sanchez BF, Montero LM, et al. The efficacy of thermotherapy to treat cutaneous leishmaniasis in Colombia: a comparative observational study in an operational setting. Trans R Soc Trop Med Hyg 2009;103(7):703-6
59. Lobo IM, Soares MB, Correia TM, et al. Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (glucantime) therapy. Trans R Soc Trop Med Hyg 2006;100(7):642-9
60. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005;366:1561-77
61. Sadeghian G, Nilfroushzadeh MA, Iraji F. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Dermatol 2007;32(4):371-4
62. Junaid AJ. Treatment of cutaneous leishmaniasis with infrared heat. Int J Dermatol 1986;25:470-72
63. van der Snoek E, Robinson D, van Hellemond J, Neumann H. A review of photodynamic therapy in cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2008;22(8):918-22
64. Pizinger K, Cetkovska P, Kacerovska D, Kumpova M. Successful treatment of cutaneous leishmaniasis by photodynamic therapy and cryotherapy. Eur J Dermatol 2009;19(2):172-3
65. Akilov OE, Kosaka S, O'Riordan K, Hasan T. Parasiticidal effect of deltaaminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells. Exp Dermatol 2007;16(8):651-60
66. Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of old world cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006;31(5):634-7
67. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996;14:417-23
68. Besch R, Poeck H, Hohenauer T, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 2009;119(8):2399-411
69. Convit J, Ulrich M, Zerpa O, et al. Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-1999. Trans R Soc Trop Med Hyg 2003;97(4):469-72
70. Machado-Pinto J, Pinto J, da Costa CA, et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. Int J Dermatol 2002;41(2):73-8
71. Musa AM, Khalil EAG, Mahgoub FAE, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 2008;102:58-63
72. Badaro R, Lobo I, Munos A, et al. Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis 2006;194(8):1151-9
73. Musa AM, Noazin S, Khalil EA, Modabber F. Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration. Trans R Soc Trop Med Hyg 2010;104(1):1-2
74. Da-Cruz AM, Filgueiras DV, Coutinho Z, et al. Atypical mucocutaneous leishmaniasis caused by Leishmania braziliensis in an acquired immunodeficiency syndrome patient: T-cell responses and remission of lesions associated with antigen immunotherapy. Mem Inst Oswaldo Cruz 1999;94(4):537-42
75. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3(2):196-200
76. Tomai MA, Miller RL, Lipson KE, et al. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines 2007;6(5):835-47
77. Zhang WW, Matlashewski G. Immunization with a toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun 2008;76(8):3777-83
78. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999;79:1485-94
79. Seeberger J, Daoud S, Pammer J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol 2003;42(7):576-9
80. Arevalo I, Tulliano G, Quispe A, et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007;44(12):1549-54
81. Miranda-Verastegui C, Tulliano G, Gyorkos TW, et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis 2009;3(7):e491
82. Krolewiecki A, Leon S, Scott P, Abraham D. Activity of azithromycin against L. major in vitro and in vivo. Am J Trop Med Hyg 2002;67:273-77
83. Tanyuksel M, Bas AL, Araz E, Aybay C. Determination of intracellular efficacies of azithromycin against Leishmania major infection in human neutrophils in vivo. Cell Biochem Funct 2003;21:93-6
84. de Oliveira-Silva F, de Morais-Teixeira E, Rabello A. Antileishmanial activity of azithromycin against Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi. Am J Trop Med Hyg 2008;78(5):745-9
85. Layegh P, Yazdanpanah MJ, Vosugh EM, et al. Efficacy of azithromycin versus systemic meglumine antimoniate (glucantime) in the treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2007;77:99-101
86. Krolewiecki AJ, Romero HD, Cajal SP, et al. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Am J Trop Med Hyg 2007;77(4):640-6
87. Miguel DC, Yokoyama-Yasunaka JK, Andreoli WK, et al. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother 2007;60(3):526-34
88. Miguel DC, Yokoyama-Yasunaka JK, Uliana SR. Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice. PLoS Negl Trop Dis 2008;2(6):e249
89. Mendez S, Traslavina R, Hinchman M, et al. The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases macrophage and dendritic cell activation. Antimicrob Agents Chemother 2009;53(12):5114-21
90. Garnier T, Brown MB, Lawrence MJ, Croft SL. In vitro and in vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis. J Pharm Pharmacol 2006;58(8):1043-54
91. Jha TK, Sundar S, Thakur CP, et al. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 2005;73(6):1005-11
92. Wasunna MK, Rashid JR, Mbui J, et al. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 2005;73(5):871-6
93. Mäntylä A, Garnier T, Rautio J, et al. Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. J Med Chem 2004;47(1):188-95
94. Garnier T, Mäntylä A, Järvinen T, et al. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J Antimicrob Chemother 2007;60(4):802-10
95. Garnier T, Mäntylä A, Järvinen T, et al. Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis. J Pharm Pharmacol 2007;59(1):41-9
96. Guiguemdé RT, Sawadogo OS, Bories C, et al. Leishmania major and HIV co-infection in Burkina Faso. Trans R Soc Trop Med Hyg 2003;97(2):168-9
97. Chrusciak-Talhari A, Ribeiro-Rodrigues R, Talhari C, et al. Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis. Am J Trop Med Hyg 2009;81(4):559-64
98. Llanos-Cuentas A, Echevarría J, Cruz M, et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 1997;25(3):677-84
99. Amato VS, Tuon FF, Imamura R, et al. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol 2009;23(9):1026-34
100. Llanos-Cuentas A, Echevarria J, Seas C, et al. Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis. Am J Trop Med Hyg 2007;76(6):1128-31
101. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007;44(3):350-6
102. Soto J, Rea J, Valderrama M, et al. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg 2009;81(3):387-9
103. de Sá Oliveira T, Capp Neto M, Martins BJ, et al. Action of pentoxifylline on experimental cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis. Mem Inst Oswaldo Cruz 2000;95(4):477-82
104. Lessa HA, Machado P, Lima F, et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 2001;65(2):87-9
105. Machado PR, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007;44(6):788-93
106. Sadeghian G, Nilforoushzadeh MA. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006;45(7):819-21
107. Gonzalez U, Pinart M, Reveiz L, Alvar J. Interventions for old world cutaneous leishmaniasis [review]. Cochrane Database Syst Rev 2008;4:CD005067 bull; An assessment of 49 trials investigating different interventions for OW disease.
108. Gonzalez U, Pinart M, Rengifo-Pardo M, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis [review]. Cochrane Database Syst Rev 2009;2:CD004834 • An assessment of 38 trials involving different interventions for NW disease.